Efficacy and Safety of Stannsoporfin in Neonates

Nutritional and Metabolic Diseases Clinical Trial

Official title:

A Multicenter Study to Evaluate the Efficacy and Safety of Tin Mesoporphyrin (Stannsoporfin) to Reduce the Need for Phototherapy in Term and Near Term Infants.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02685137
• Other study ID #: 64,185-01-3W
• Status: Completed
• Phase: Phase 3
• Start date: May 1, 2002
• Est. completion date: February 2013

Study information

• Verified date: June 2018
• Source: Mallinckrodt
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, randomized, sham injection-controlled (placebo) masked trial of a single intramuscular injection of Stannsoporfin compared to "sham" (placebo) in healthy term and near-term newborns admitted to the well-baby nursery and enrolled with "intention to treat".

Description:

For purposes of analysis, 2 patient populations are defined. One population consists of those babies who did not develop severe hyperbilirubinemia (TSB <9 mg/dL) during the first 36 hours of age. This population is referred to as the untreated population of screened but not randomized patients. The second population of babies was defined as those infants who develop severe hyperbilirubinemia. These infants were randomized to treatment with either stannsoporfin or the sham injection and will be the focus of the efficacy and safety analysis. This population was referred to as the treated population.

The treated population was used for the efficacy and safety analysis. These infants were randomized to either stannsoporfin or the sham injection treatment group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: February 2013
• Est. primary completion date: March 16, 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 36 Hours

Eligibility

Patients were enrolled who meet the following criteria:

1. The infant's family may be approached at anytime from 6 hours after birth onward to discuss the possibility of enrollment. However, Informed Consent may not be signed until the baby is between 12 and 36 hours of age.

2. Consent may be obtained as soon as possible after 12 hours of age, when the baby enters the well-baby nursery.

3. An infant may be included if the mother has received, or the baby is receiving, antibiotics and the infant is asymptomatic. For example, the baby has no signs of cardiorespiratory distress and is feeding well. Symptomatic infants are excluded (see Exclusions, below).

4. Born at the study hospital site and admitted to the well-baby nursery or admitted to the intensive-care nursery for <12 hours for post delivery observation (delayed transition, temperature or dextrose instability, meconium staining and/or parental concern).

5. All babies on oral feeding with stable cardiorespiratory status and deemed "healthy" upon clinical examination, with normal perfusion as defined by capillary filling of the fingernail.

6. Term neonate (=38 weeks of completed gestation), OR

7. Near-term neonate (>36<38 weeks of completed gestation; >2,000g birth weight), OR

8. Near-term neonate (>35<38 weeks of completed gestation; >2,500g birth weight)

9. Care provided (primarily) in the well-baby nursery population;

10. Absence of concurrent cardiorespiratory distress, sepsis, major congenital anomalies or need for care in an intensive care nursery;

11. Not participating in another concurrent unrelated study.

Exclusion Criteria

The study enrolled patients who did not have any of the following exclusion criteria:

1. Any condition that in the opinion of the investigator would make the subject unsuitable for the study.

2. Infants receiving antibiotics who are also symptomatic are excluded. For example, a baby who is feeding poorly or is in cardiorespiratory distress is excluded.

3. Mother has received phenobarbital in past 30 days.

Related Conditions & MeSH terms

• Metabolic Diseases
• Nutritional and Metabolic Diseases

Intervention

Drug:
• stannsoporfin
Intramuscular injection of stannsoporfin to treat jaundice.

Other:
• Sham Injection
nothing

Locations

Country	Name	City	State
United States	Pennsylvania Hospital	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Need for Phototherapy	proportion of cases which need phototherapy in the treated population	30 days
Secondary	hyperbilirubinemia	Change in serum bilirubin values	12 hrs